首页 | 本学科首页   官方微博 | 高级检索  
     

分子分型与前哨淋巴结阳性乳腺癌患者非前哨淋巴结转移的相关性分析
引用本文:王娜娜,王 雪,陈丽璇,张 斌. 分子分型与前哨淋巴结阳性乳腺癌患者非前哨淋巴结转移的相关性分析[J]. 天津医科大学学报, 2018, 0(5): 437-441
作者姓名:王娜娜  王 雪  陈丽璇  张 斌
作者单位:天津医科大学肿瘤医院乳腺肿瘤一科,国家肿瘤临床医学研究中心,天津市“肿瘤防治”重点实验室,天津市恶性肿瘤临床医学研究中心,乳腺癌防治教育部重点实验室,天津300060
摘    要:目的:分析前哨淋巴结(SLN)阳性乳腺癌患者分子分型与非前哨淋巴结转移(NSLN)的相关性。方法:回顾性分析前哨淋巴结阳性且行腋窝淋巴结清扫术的274例浸润性导管癌患者的临床病理资料,对可能影响NSLN状态的变量进行单因素及多因素Logistic回归分析。结果:274例前哨淋巴结阳性患者中,NSLN转移92例(33.6%)。单因素分析结果显示,肿瘤大小(P=0.013)、脉管浸润(P =0.031)、SLN转移灶大小(P=0.002)、SLN(+)/SLN比率(P<0.001)、分子分型(P<0.001)与NSLN转移相关。多因素分析结果显示,肿瘤大小(OR=1.452;95% CI:1.020-2.068;P=0.039)、SLN微转移(OR=0.140;95% CI:0.030-0.663;P=0.013)、SLN(+)/SLN比率(OR=3.533;95%CI:1.834-6.806;P <0.001)以及分子分型是NSLN转移的独立预测因素。以Luminal A作为参考,Luminal B(OR=3.994,95% CI:1.961-8.131;P<0.001)和HER2过表达型(OR=3.252;95% CI:1.057-10.004;P=0.040)发生NSLN转移的风险显著增加,而三阴性乳腺癌发生NSLN转移风险并未明显增加(OR=1.560;95%CI:0.658-3.698;P =0.313)。结论:乳腺癌分子分型是前哨淋巴结阳性乳腺癌NSLN转移的独立预测因素,Luminal B和HER2过表达型更易出现NSLN转移。

关 键 词:乳腺癌  分子分型  前哨淋巴结  非前哨淋巴结转移

Correlation analysis between molecular subtype and non-sentinel lymph node metastasis in breast cancer patietns with positive sentinel lymph nodes
WANG Na-na,WANG Xue,CHEN Li-xuan,ZHANG Bin. Correlation analysis between molecular subtype and non-sentinel lymph node metastasis in breast cancer patietns with positive sentinel lymph nodes[J]. Journal of Tianjin Medical University, 2018, 0(5): 437-441
Authors:WANG Na-na  WANG Xue  CHEN Li-xuan  ZHANG Bin
Affiliation:First Department of Breast Surgery, Cancer Institute and Hospital, Tianjin Medical University, National Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin’s Clinical Research Center for Cancer; Tianjin 300060, China
Abstract:Objective: To analyze whether molecular subtype is associated with non-sentinel lymph nodes (NSLN) metastasis and explore the risk factors for NSLN metastasis in patients with a positive SLN. Methods: The clinicopathologic data of 274 breast cancer patients with sentinel lymph node metastasis who underwent axillary lymph node dissection were collected. Independent risks for non-sentinel lymph node metastasis were assessed by univariate and multivariate analyses. Results:NSLN metastasis was found in 92(33.6%) of 274 patients with a positive SLN. Based on the results of the univariate analysis, the variables that were significantly associated with the incidence of NSLN metastasis in a SLN positive patient included tumor size (P=0.013), the size of SLN metastasis (P =0.002), lymphovascular invasion (P =0.031), the ratio of positive SLN(P<0.001) and molecular subtype(P<0.001). Using multivariate analysis, tumor size(OR = 1.452; 95% CI: 1.020-2.068; P = 0.039), the size of SLN metastasis(OR = 0.140; 95% CI: 0.030-0.663;P = 0.013), the ratio of positive SLN(OR=3.533 95%CI: 1.834-6.806;P<0.001) and molecular subtype were identified as independent predictors for non-SLN metastasis. Patients with Luminal B (OR=3.994; 95% CI: 1.961-8.131; P<0.001) and HER2 overexpression subtypes (OR=3.252; 95% CI:1.057-10.004; P=0.040) had a higher risk of NSLN metastasis than patients with the Luminal A subtype. However, patients with triple negative subtype did not have a higher risk than patients with Luminal A subtype (OR=1.560; 95%CI:0.658-3.698;P=0.313). Conclusion: Except for other factors, molecular subtype is a independent predictor for NSLN metastasis in patients with a positive SLN. Luminal B and HER2 overexpression subtypes have a higher risk of NSLN metastasis than patients with the Luminal A subtype and triple negative breast cancer.
Keywords:breast cancer  molecular subtype  sentinel lymph node  non-sentinel lymph node metastasis
点击此处可从《天津医科大学学报》浏览原始摘要信息
点击此处可从《天津医科大学学报》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号